Inhibition of cytokine production by the traditional oriental medicine, 'Gamcho-Sasim-Tang' in mitogen-stimulated peripheral blood mononuclear cells from Adamantiades-Behçet's patients

Journal of Ethnopharmacology

Volumn 83, Issue 1-2, 2002, Pages 123-128

  Kim, Mi Sun ^a,b   Chung, Hwan Suck ^a   Lee, Jun Gyoung ^a   Lim, Woon Ki ^b   Hwang, Chung Yeon ^c   Lee, Eon Jeong ^c   Cho, Kwang Ho ^d   Wi, Dac Han ^d   Kim, Hyung Min ^a  

^a Wonkwang University   (South Korea)

^b Pusan National University   (South Korea)

^c Wonkwang University   (South Korea)

^d Wonkwang University School of Medicine   (South Korea)

Author keywords

Adamantiades Beh et's disease; Gamcho Sasim Tang; IFN ; IL 1 ; TNF

Indexed keywords

GAMCHO SASIM TANG EXTRACT; GAMMA INTERFERON; INTERLEUKIN 1BETA; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAMANTIADES BEHCET DISEASE; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHCET DISEASE; BLOOD; CASE REPORT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FEMALE; GAMCHO SASIM TANG; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY DISEASE; MALE; MEDICINAL PLANT; MODULATION; MONONUCLEAR CELL; PATHOGENESIS;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; CYTOKINES; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHYTOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036877015     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-8741(02)00221-0     Document Type: Article

References (43)

1. Al-Dalaan A., al-Sedairy S., al-Balaa S., al-Janadi M., Elramahi K., Bahabri S., Siddiqui S. Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease. The Journal of Rheumatology. 22:1995;904-907.
2. Arbesfeld S.J., Kurban A.K. Behçet's disease. New perspectives on an enigmatic syndrome. Journal of American Academic Dermatology. 19:1988;767-779.
3. Bacon T.H., Ozbakir F., Elms C.A., Denman A.M. Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome. Clinical and Experimental Immunology. 57:1984;541-547.
4. Bang D.S. Treatment of Behçet's disease. Yonsei Medical Journal. 38:1997;401-410.
5. Bang D., Hur W., Lee E.S., Lee S. Prognosis and clinical relevance of recurrent oral ulceration in Behçet's disease. Journal of Dermatology. 22:1995;926-929.
6. Bondeson J., Maini R.N. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (Remicade). International Journal of Clinical Practice. 55:2001;211-216.
7. Calabrese L., Fleischer A.B. Thalidomide: current and potential clinical applications. American Journal of Medicine. 108:2000;487-495.
8. Chabaud M., Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis and Rheumatism. 44:2001;1293-1303.
9. Chertov O., Michiel D.F., Xu L., Wang J.M., Tani K., Murphy W.J., Longo D.L., Taub D.D., Oppenheim J.J. Indentification of defensin-1, defensin-2, and CAP37/Azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. Journal of Biological Chemistry. 271:1996;2935-2940.
10. Emmi L., Salvati G., Brugnolo F., Marchione T. Immunopathological aspects of Behçet's disease. Clinical and Experimental Rheumatology. 13:1995;687-691.
11. Fujii N., Minagawa T., Nakane A., Kato F., Ohno S. Spontaneous production of gamma-interferon in cultures of T lymphocytes obtained from patients with Behçet's disease. Journal of Immunology. 130:1983;1683-1686.
12. Hamzaoui K., Hamza M., Ayed K. Production of TNF-α and IL-1 active Behçet's disease. The Journal of Rheumatology. 17:1990;1428-1429.
13. Hassard P.V., Binder S.W., Nelson V., Vasiliauskas E.A. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: case report. Gastroenterology. 120:2001;995-999.
14. Jeong H.J., Hong S.H., Kim S.C., Park E.J., Jang C.H., Kim K.S., Kim H.M. Effects of Allergina on the treatment of otitis media with effusions. Inflammation. 26:2002;89-95.
15. Kaklamani V.G., Vaiopoulos G., Kaklamanis P.G. Behçet's disease. Semin Arthritis and Rheumatism. 27:1998;197-217.
16. Kastner D.L. Intermittent and periodic arthritic syndromes. Koopman W.J. 13th ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. 1:1997;1279-1306 Williams & Wilkins, Baltimore.
17. Katayama T., Tachinami K., Ishiguro M., Kubota Y. The relation between Behçet's disease and interleukin-1β production. Nippon Ganka Gakkai Zasshi. 98:1994;197-201.
18. Katsantonis J., Adler Y., Orfanos C.E., Zouboulis C.C. Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology. 201:2000;37-39.
19. Kim H.J., Chae B.Y. Clinical observation of Behçet's disease patients by Oriental medicine. The Journal of Oriental Medical Surgery, Ophthalmology and Otolaryngology. 12:1999;387-395.
20. Kim H.M., Lee E.H., Cho H.H., Moon Y.H. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by spiulina. Biochemical Pharmacology. 55:1998;1071-1076.
21. Kim H.M., Lee Y.M. Role of TGF-β1 on the IgE-dependent anaphylaxis reaction. Journal of Immunology. 162:1999;4960-4965.
22. Kotake S., Higashi K., Yoshikawa K., Sasamoto Y., Okamoto T., Matsuda H. Central nervous system symptoms in patients with Behçet disease receiving cyclosporin therapy. Ophthalmology. 106:1999;586-589.
23. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., Inaba G. Double-masked trial of cyclosporin versus colchcine and long-term open study of cyclosporin in Behçet's disease. Lancet. 1:1989;1093-1096.
24. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., Ewan P.W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral mononuclear cell cultures. Clinical and Experimental Immunology. 99:1995;160-167.
25. Mege J.L., Dilsen N., Sanguedolce V., Gul A., Bongrand P., Roux H., Ocal L., Inanç M., Capo C. Overproduction of monocyte derived tumor necrosis factor α, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. The Journal of Rheumatology. 20:1993;1544-1549.
26. Na H.J., Jeong H.J., Bae H., Kim Y.B., Park S.T., Yun Y.G., Kim H.M. Tongkyutang inhibits mast cell-dependent allergic reactions and inflammatory cytokines secretion. Clinica Chimica Acta. 319:2002;35-41.
27. Nakae K., Masaki F., Hashimoto T., Inaba G., Mochizuki M., Sakane T. Recent epidemiological features of Behçet's disease in Japan. Wechsler B., Godeau P. Behçet's disease. 1993;Excerpta Media, Amsterdam.
28. Nussenblatt R.B. Uveitis in Behçet's disease. International Review of Immunology. 14:1997;67-79.
29. Ozoran K., Aydintug O., Tokgöz G., Düzgün N., Tutkak H., Gürler A. Serum levels of interleukin-8 in patients with Behçet's disease. Annals of the Rheumatic Diseases. 54:1995;610.
30. Ozyazgan Y., Yurdakul S., Yazici H., Tuzun B., Iscimen A., Tuzun Y., Aktunc T., Pazarli H., Hamuryudan V., Muftuoglu A. Low dose cyclosporin A versus plused cyclophosphamide in Behçet's syndrome: a single masked trial. British Journal of Ophthalmology. 76:1992;241-243.
31. Poulter L.W., Lehner T. Immunohistology of oral lesions from patients with resurrent oral ulcers and Behçet's syndrome. Clinical and Experimental Immunology. 78:1989;189-195.
32. Sakane T., Takeno M. Novel approaches to Behçet's disease. Expert Opinion Investigative Drugs. 9:2000;1993-2005.
33. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. The New England Journal of Medicine. 341:1999;1284-1291.
34. Sakuma S., Kato Y., Nishigaki F., Magari S., Miyata S., Ohkubo Y., Goto T. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. International Immunopharmacology. 1:2001;749-757.
35. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. Journal of Experimental Medicine. 173:1991;699-703.
36. Sayinalp N., Özcebe O.I., Özdemir O., Haznedaroglu I.C., Dündar S., Kirazli S. Cytokines in Behçet's disease. The Journal of Rheumatology. 23:1996;321-322.
37. Shin H.Y., Jeong H.J., Lee J.H., Joo J.C., Kim K.Y., Song H.J., Lee S.G., Chae H.J., Kim H.R., Kim J.J., Kim H.M. Regulatory effect of cytokine production in patients with cerebral infarction by Yulda-hanso-tang. Immunopharmacology and Immunotoxicology. 22:2000;183-193.
38. Taub D.D., Anver M., Oppenheim J.J., Longo D.L., Murphy W.J. T lymphocyte recruitment by interleukin-8 (IL-8). Journal of Clinical Investigation. 97:1996;1931-1941.
39. Wright D.C., Deol H.S., Tuch B.E. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transplant Immunology. 7:1999;141-147.
40. Yazici H., Yurdakul S., Hamuryudan V. Behçet's syndrome. Current Opinion in Rheumatology. 11:1999;53-57.
41. Yosipovitch G., Shohat B., Bshara J., Wysenbeek A., Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1b in patients with Behçet's disease: correlations with disease activity and severity. Israel Journal of Medical Science. 31:1995;345-348.
42. Zouboulis C.C. Epidemiology of Adamantiades-Behçet's disease. Annales de Medecine Interne. 150:1999;488-498.
43. Zouboulis C.C., Katsantonis J., Ketteler R., Treudler R., Kaklanmani E., Hornemann S., Kaklamanis P., Orfanos C.E. Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Archives of Dermatological Research. 292:2000;279-284.